Skip to main content
. 2015 Feb 17;12(1):83–92. doi: 10.3892/mmr.2015.3368

Figure 5.

Figure 5

Targeting Akt inhibits the proliferation and angiogenic potential of SCLC cells. (A) Growth curves of cells in the control, CPA-7 and wortmannin groups. Following treatment with the Akt inhibitor wortmannin, the growth rate was significantly decreased; however, when treated with STAT3 inhibitor CPA-7, the growth curve was vimilar to that of the control group (NCI-H446/wortmannin group vs. NCI-H446/control group, P<0.05; NCI-H446/CPA-7 group vs. NCI-H446/control group, P>0.05). (B) Western blot analysis of VEGF-A protein expression. Representative images of three independent experiments and quantified results normalized to β-actin are shown. Following treatment with wortmannin, VEGF-A expression was significantly inhibited, but following treatment with CPA-7, VEGF-A expression exhibited no significant change (NCI-H446/wortmannin group vs. NCI-H446/control group, P<0.05; NCI-H446/CPA-7 group vs. NCI-H446/control group, P>0.05). (C) CD34 expression in three groups (magnification, x200). Immunofluorescence staining showed that following treatment with wortmannin, the CD34 expression was significantly decreased, while following treatment with CPA-7, CD34 expression was not significantly change. VEGF, vascular endothelial growth factor; SCLC, small cell lung cancer.